New York, NY -- (SBWIRE) -- 12/05/2013 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: JPMorgan Chase & Co (NYSE:JPM), Boyd Gaming Corporation (NYSE:BYD), Idera Pharmaceuticals Inc (NASDAQ:IDRA), Blue Earth Inc (OTCMKTS:BBLU)
JPMorgan Chase & Co (NYSE:JPM) the stock opened the session at $56.44 but then moved to $57.19. At that price, the stock showed a positive performance of 0.58%. JPMorgan Chase & Co. (JPMorgan Chase) is a financial holding company. The Company is a global financial services firm and a banking institution in the United States, with global operations. The Company is engaged in investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, asset management and private equity. JPMorgan Chase’s principal bank subsidiaries are JPMorgan Chase Bank,
Will JPM Continue To Move Higher? Find Out Here
Boyd Gaming Corporation (NYSE:BYD) opened the session at $11.07 and closed the session at $11.34. The stock showed a positive performance of 2.72% in previous trading session. Boyd Gaming Corporation (Boyd Gaming), incorporated in June 1988, is a multi-jurisdictional gaming company. The Company is an operator of 16 wholly owned gaming entertainment properties and one controlling interest in a limited liability company. It has gaming operations in Nevada, Illinois, Louisiana, Mississippi, Indiana and New Jersey. It operates in four segments: Las Vegas Locals, Downtown Las Vegas, Midwest and South, and Atlantic City. The Company owns and operates a travel agency in Hawaii,
For How Long BYD will fight for Profitability? Read This Trend Analysis report
Idera Pharmaceuticals Inc (NASDAQ:IDRA) opened the session at $2.03 and closed the session at $2.45. The stock showed a positive performance of 21.89% in previous trading session. The beta of the stock remained -1.94. Idera Pharmaceuticals, Inc. is a clinical-stage biotechnology company engaged in the discovery and development of novel synthetic deoxyribonucleic acid (DNA) - and ribonucleic acid (RNA) - based drug candidates. The Company is developing drug candidates that are designed to modulate immune responses mediated through Toll-like Receptors (TLRs). It is also evaluating gene silencing oligonucleotides (GSOs), which inhibit the production of disease-associated proteins by targeting RNA.
Why Should Investors Buy IDRA After The Recent Gain? Just Go Here and Find Out
Blue Earth Inc (OTCMKTS:BBLU) the stock decreased -6.10% and finished the session at $2.00. Traded with volume of 424,709.00 shares in the prior session and the average volume of the stock remained 95,790.00 shares. The beta of the stock remained 140.04. Blue Earth, Inc. is engaged in a mergers and acquisition in the clean-tech industry. The Company primary focus is acquiring companies and technologies that serve the energy efficiency services and renewable energy market sectors. Its technologies include various measures designed for a specific customer or facility in its target market of small commercial businesses and residences to improve the efficiency of building systems, such as refrigeration, lighting and heating, ventilation and air conditioning.
Will BBLU Get Buyers Even After The Recent Rally? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)